Clinical Trials Logo

Acute Alcoholic Hepatitis clinical trials

View clinical trials related to Acute Alcoholic Hepatitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT02612428 Terminated - Clinical trials for Acute Alcoholic Hepatitis

Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

Start date: January 2016
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) through at least Study Day 91. The secondary objective is to evaluate the proportion of survivors at Study Day 91 using a chi-squared test.

NCT ID: NCT01937130 Terminated - Liver Cirrhosis Clinical Trials

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Start date: September 2013
Phase: Phase 2
Study type: Interventional

The study will evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of IDN-6556 in subjects with cirrhosis of the liver who are hospitalized for more than 24 hours due to acute deterioration of liver function.

NCT ID: NCT01922895 Suspended - Clinical trials for Acute Alcoholic Hepatitis

Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis

NTAH-Mod
Start date: August 2013
Phase: N/A
Study type: Interventional

This study is being done to find out whether a diet supplemented with a probiotic nutrient can improve alcoholic hepatitis and gut complications compared to routine standard care.

NCT ID: NCT01809132 Completed - Clinical trials for Acute Alcoholic Hepatitis

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

Start date: September 2013
Phase: Phase 2/Phase 3
Study type: Interventional

This study will compare two different treatments of acute alcoholic hepatitis. The current standard of care is treatment with corticosteroids (methylprednisolone). This will be compared to treatment with anakinra, pentoxifylline, plus zinc sulfate. The participants will be treated and followed for 6 months and the two treatment groups will be compared for differences in death rates and laboratory tests that measure liver and gut function.

NCT ID: NCT01471028 Completed - Clinical trials for Acute Alcoholic Hepatitis

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

Start date: February 2013
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate safety and efficacy of ELAD® with respect to overall survival (OS) of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) up to at least Study Day 91, with follow-up Protocol VTI-208E providing additional survival data up to a maximum of 5 years that will be included, as available, through VTI-208 study termination (after the last surviving enrolled subject completes Study Day 91). Secondary objectives are to determine the proportion of survivors at Study Days 28 and 91. Exploratory objectives are to evaluate the ability of ELAD to stabilize liver function, measured using the Model for End Stage Liver Disease (MELD)-based time to progression (TTP) up to Study Day 91, and the proportion of progression-free survivors (PFS) up to Study Days 28 and 91. Progression is defined as death or the first observed increase of at least 5 points from End of Study Day 1 MELD score (for both the ELAD and Control groups) until at least 24 hours after the ELAD Treatment Period is ended (end of Day 7 for Controls) and up to both End of Study Days 28 and 91 following Randomization.